| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

Home 
 
 News
 Irish
 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 International
 Property
 Innovation
 
 Analysis/Comment
 
 Asia Economy

RSS FEED


How to use our RSS feed

 
Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.

Welcome

Finfacts is Ireland's leading business information site and you are in its business news section.

We provide access to live business television and business related videos from: Bloomberg TV; The Wall Street Journal; CNBC and the Financial Times. Click image:

Links

Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Irish Economy

Global Income Per Capita

Global Cost of Living

Irish Tax 2008

Climate Change Reports

Global News

Bloomberg News

CNN Money

Cnet Tech News

Newspapers

Irish Independent

Irish Times

Irish Examiner

New York Times

Financial Times

Technology News

 

Feedback

 

Content Management by interactivetools.com.

News : Irish Last Updated: Apr 24, 2009 - 5:31:05 PM


NUI Galway partners with Beckman Coulter to commercialise biomedical research
By Finfacts Team
Feb 13, 2008 - 12:42:25 PM

Email this article
 Printer friendly page

Irish State agency Enterprise Ireland says biomedical research at NUI Galway is "revolutionising" the way patients can be cared for and creating high-value research jobs in the process. 

Technologies developed at the university, with funding from Enterprise Ireland, have attracted significant investment from global biomedical testing leader, Beckman Coulter. Beckman Coulter has now established a new Irish-based company, Beckman Coulter Biomedical Ltd. and has signed a four year, multi-million euro collaborative research agreement with NUI Galway which will see the creation of a team of 10 Masters and PhD researchers, based in Galway, to carry out the research programme.

This strategic investment by Enterprise Ireland in technology and IP development  has been key to attracting Beckman Coulter to develop, in Ireland, products for molecular diagnostics worldwide.  Further investment from IDA now supports Beckman Coulter’s decision to grow this business from Galway.

No figures have been published on the investment nor the commitment by Beckman Coulter. We are awaiting information on whether patents have been granted in respect of the technologies.   

Enterprise Ireland says it has been working with NUI Galway on the development and commercialisation of these technologies for almost 10 years, providing research and patent funding and support in finding industrial partners for the emerging technologies. The two main technologies, developed by Dr Tom Barry, Dr. Majella Maher and Professor Terry Smith at NUI Galway, are fundamental to Beckman Coulter’s “sample to result” molecular diagnostics strategy.  

Beckman Coulter plans to develop a molecular platform and has invested in several technology acquisitions and licenses.  The NUI Galway Nucleic acids gene targets are the enabling technology that will unite the underpinning technologies in which Beckman Coulter has already invested.

The agreement with NUI Galway provides Beckman Coulter with “access to intellectual property for the development of tests for infectious diseases including sepsis; hospital-acquired infections; and sexually transmitted diseases, such as Chlamydia and Neisseria,” said Mike Whelan, group vice president of Beckman’s High Sensitivity Testing group.

Dr Paul Roben, Director of Lifescience & Food Commercialisation at Enterprise Ireland said, “Enterprise Ireland continues to support NUI Galway as the university’s biomedical research strategy evolves to bring cutting-edge solutions to the  needs of patients in the healthcare system and bring economic benefits to Ireland.  We are delighted to see these research and commercialisation efforts come to fruition.”

"We are excited to partner with Beckman Coulter on this unique initiative," said Dr. Daniel O'Mahony, Director, Technology Transfer at NUI Galway. "It underpins our commitment to, and support of, research excellence and exemplifies our stated research strategy: creating an environment that values intellectual property and promoting technology transfer and commercialization activity among University researchers and industry partners. This collaboration brings together molecular diagnostic expertise at NUI Galway with automated solution expertise at Beckman Coulter that will result in the development of breakthrough technologies for the diagnosis of a variety of infectious diseases in humans."

Beckman Coulter, Inc. is a manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes. Spanning the biomedical testing continuum—from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing—Beckman Coulter's 200,000 installed systems provide essential biomedical information to enhance health care around the world. The company, based in Fullerton, California, reported 2006 annual sales of $2.53 billion with 75 percent of this amount generated by recurring revenue from supplies, test kits and services.

The principal link is at the bottom of the list below. 

Related Articles
Related Articles


© Copyright 2009 by Finfacts.com

Top of Page

Irish
Latest Headlines
Ryanair revises up full-year profit guidance
AIB bank profitable in third quarter
Ryanair announces half-year profits up 32% to €795m
Ryanair benefits from improved customer service
Ryanair to buy 100 new Boeing 737 MAX 200
Finfacts server migration Thursday
State-owned Allied Irish Banks reports H1 2014 profit as bad loan charges plunge
Ryanair reports profit in its financial first quarter soared 152%
UK firm opens van dealership in Dublin
Ryanair reports 8% fall in full-year profit; US services to commence in 2019
Global Financial Centres Index: New York overtakes London; Dublin slips to 66 of 83 cities
Bank of Ireland reports “significant” improvement in 2013 results
Sale process of IBRC UK projects Rock and Salt completed
CRH says 2014 will be year of profit growth after reporting 2013 loss
Ryanair reports third-quarter loss
Irish Water says it saved €100m in setup costs
RSA Insurance fires two Irish executives for large loss/ accounting irregularities
Bank of Ireland will have to raise provisions by €1.4bn; AIB says it's "well capitalised"
CRH reports slightly improved third quarter
Central Bank says ownership of Newbridge Credit Union transferred to permanent tsb
Ryanair reports H1 profits rose by 1% to €602m
Dublin Web Summit: Irish Stock Exchange and NASDAQ OMX announce dual listing plan
Irish pension managed funds returned to growth during September
Dan O’Brien resigns as economics editor of The Irish Times
Central Bank says no action required on Anglo tapes revelations
Ryanair flew 9m passengers and Aer Lingus carried 1.1m in August
UK Competition Commission says Ryanair must cut Aer Lingus stake to 5%
CRH reports H1 2013 revenue dip and loss
Vodafone refunded UK after discovery of Irish tax haven deal
RBS reports half year profit; Ulster Bank posts reduced loss
Bank of Ireland cuts pretax losses in HI 2013 to €504m
Irish State-owned Allied Irish Banks reports losses of €758m in H1 2013
Service Announcement
Irish managed pension funds declined in June
VHI reports 2012 surplus of €54.3m; Health insurance made loss
Ex- Elan director says management / board "not competent to run a business"
Aer Lingus to put €140m in employees pensions fund; Ryanair apoplectic
Wednesday Newspaper Review - Irish Business News and International Stories - - May 22, 2013
Tuesday Newspaper Review - Irish Business News and International Stories - - May 21, 2013
Ryanair, Europe’s biggest low cost carrier, announced Monday record annual profits of €569m - - up 13%